Fig. 4. Randomised comparison of non-breast cancer mortality showing signifcantly fewer deaths in patients randomised to TARGIT-IORT(top graph), and non-randomised comparisons to assess the contribution to the difference seen in the randomised comparison: because of the delivery of TARGIT-IORT (bottom left), and the avoidance of EBRT (bottom right).

Please note that 40% of patients in the 1158 EBRT arm also received a tumour-bed boost which was not given to those who had received TARGIT-IORT.